01.08.2004
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study
Erschienen in: Investigational New Drugs | Ausgabe 3/2004
Einloggen, um Zugang zu erhalten